Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed Acute Lymphoblastic Leukemia: early-phase trial registry
1 of 3 indexed Relapsed Acute Lymphoblastic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Relapsed Acute Lymphoblastic Leukemia: 3 US clinical trials tracked, 1 recruiting.
Relapsed Acute Lymphoblastic Leukemia is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Tanja Andrea Gruber, running 1 of these trials.
Enrollment posture brief
Registry condition relapsed-acute-lymphoblastic-leukemia
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Relapsed Acute Lymphoblastic Leukemia lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed Acute Lymphoblastic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed Acute Lymphoblastic Leukemia is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
Tanja Andrea Gruber
NCT04996160
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
NCT05192889
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
NCT03575325
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed Acute Lymphoblastic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed Acute Lymphoblastic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed Acute Lymphoblastic Leukemia page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Relapsed Acute Lymphoblastic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Tanja Andrea Gruber sponsors the most Relapsed Acute Lymphoblastic Leukemia trials on record, review their full trial history before evaluating a specific study. See Tanja Andrea Gruber's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed Acute Lymphoblastic Leukemia condition card totals 3 registered trials; most-linked intervention Dexamethasone; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.